ACell, Inc. develops and manufactures bioscaffold, extracellular matrix technology for medical and veterinary products. It offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix devices to repair and remodel damaged tissues and organs in a broad range of surgical procedures. The firm's products include ABRA, Cytal Burn Matrix, Cytal Wound Matrix, Gentrix Surgical Matrix and MicroMatrix. It is a regenerative medicine company that focuses on the development, manufacturing and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects. The firm’s products utilizes proprietary porcine urinary bladder matrix platform technology, which is designed to enhance the body's ability to restore natural tissue and minimize scarring in the management of traumatic, surgical and chronic wounds, burns, hernias and other conditions requiring the reinforcement of soft tissue. The company was founded by Stephen Xavier Graham in June 1999 and is headquartered in Columbia, MD.

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

Arthrex GmbH, a subsidiary of Arthrex, Inc., is a German company located in Munich that manufactures orthopedic devices. Stefan Krupp is currently the CEO of the firm.

TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.

Opocrin SpA engages in the manufacture and marketing of active ingredients for the pharmaceutical industry. Its products include Collagen Gel, Sodium and Calcium Heparin, Iron Complexes, Parnaparin, and Pulmonary Surfactant. The company was founded by Pietro Bianchini in 1964 and is headquartered in Modena, Italy.

The Group has strengthened its presence in Italy and has grown to become an international pharmaceutical company. The research for the development of original and innovative products, to improve the health and quality of life of people, is an integral and fundamental part of the activities of the company that has fully developed four products and, over the years, has obtained over 700 patents for more than 40 countries . The Group enjoys an image of seriousness and dynamism and believes in promoting the culture of Corporate Social Responsibility in order to provide a service to the community.

Smith & Nephew PLC designs, manufactures and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is a sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

CorNeat Vision is a clinical-stage, biomimetic implants and technology company. Our patented, nondegradable, synthetic, platform material - The CorNeat EverMatrix™ - is set to displace harvested and processed human and animal tissues, and degradable Extra Cellular Matrices (ECMs), the protein skeleton of the tissue, used in a variety of surgical procedures across diversified fields of medicine. The CorNeat EverMatrix™ addresses the main issue with implants and implantables – the foreign body response they trigger leading either to their degradation and absorbance, or encapsulation. The CorNeat EverMatrix™ seamlessly and permanently embeds with live tissue without triggering an inflammatory response. Its durability and flexibility, coupled with its bio-integration capabilities, mark a new era of implants that can: • Bio-mechanically integrate with surrounding tissue • Permanently reinforce soft tissue and accelerate its healing • Act as a membrane for guided soft tissue and bone regeneration • Conceal irritating implants • Enable sensors to continuously remain in contact with surrounding tissue The features and benefits of the CorNeat EverMatrix™ were proven histologically and clinically in over a dozen in-vitro and in-vivo studies, including in humans.

Syntacoll Gmbh, part of Innocoll Holdings Plc, is a company headquartered in Saal an der Donau, Germany. The firm manufactures pharmaceutical products. It was founded in 1992. Alexandra Dietrich is the CEO, in this role since 2006.

Markman Biologics is a biotechnology company that has obtained a series of novel patents that pertain to Micro Resurfacing of Internal and External Medical Reconstructive tissue grafts. Its mission is to broaden and advance its application in a multitude of wound healing scenarios. Markman Biologics will strive to be at the forefront and best in class for continuous improvement in their medical applications.

Regentys, (“Asana” or the “Company”) is an early‐stage Florida corporation focused on the development and commercialization of innovative medical devices for gastrointestinal applications. Asana’s lead product, ExtraCellular Matrix Hydrogel (ECMH), is a hydrogel composed of extracellular matrix derived from porcine tissue. ECMH creates an environment favorable for the body to grow new tissue in place of diseased or damaged tissue. Extracellular matrix has been proven to be safe and effective in esophageal repair, hernia grafts, vaginal slings, and burn and wound dressings. Asana’s novel application of this technology will treat ulcerative colitis (UC), a debilitating disease that renders the colon dysfunctional.

Reminova aims to improve oral healthcare and to transform how dentist’s treat dental caries (tooth decay). The company is developing a new treatment for dentists to use in treating early stage tooth decay (caries) that repairs the damaged enamel back to a strong and healthy condition in a rapid treatment. There is no drilling, no filling and no need for anaesthetic injections in our painless remineralization procedure. Reminova’s natural preventative treatment, that can enable everyone to keep their own teeth strong and healthy for the whole of their life.

BellaSeno GmbH is a German private company located in Leipzig that manufactures preclinical stage medical devices. It was founded in 2016 by Holger Buck, Dietmar W. Hutmacher, Mohit P Chhaya, Jan-Thorsten Schantz and Paul Severin Wiggenhauser. Mohit P Chhaya is currently the CEO of the firm.

Cook Biotech, Inc., a subsidiary of Cook Group, Inc., is a company headquartered in West Lafayette, IN, that develops and manufactures medical products for tissue repair and regenerative medicine applications. The firm was founded in 1963.\nThe company says this about itself: Cook Biotech Inc. develops and manufactures medical products for tissue repair and regenerative medicine applications using proprietary extracellular matrix (ECM) technologies and processes. Cook Biotech products are marketed and distributed under several brand names, including Biodesign® and OASIS®. Cook Biotech collaborates with partners and distributors, including AxoGen Inc., Aziyo Biologics, Cook Medical Inc., Cormatrix, Katena Products Inc., Keystone Dental Inc., and Smith & Nephew Inc., to develop new products and provide technical support. Cook Biotech was established in 1995 and is affiliated with Cook Medical Holdings in Bloomington, Indiana. It is located in the Purdue Research Park in West Lafayette, Indiana.

Boston Scientific Scimed, Inc. develops, manufactures, and markets medical devices used principally to treat cardiovascular disease.

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

Natural Implant SA develops and manufactures dental implants from biomaterial. The company manufactures a novel type of dental implant made from an FDA biomaterial around which it grows periodontal ligament cells using tissue engineering techniques. Natural Implant was founded in 1998 and is headquartered in Brest, France.

GC Corp. is a private company headquartered in the United States with domestic subsidiaries, involved in venture capital/private equity.

Hefei Huijia Medical Technology Co., Ltd., established on 2016-12-29, Business scope includes medical devices(one type,Class II),Prosthetic orthotics,Rehabilitation Aids Accessories,Fitness Equipment,Software development,Production,to assemble,make,Sales;Life Science Instruments and Equipment,Research and development of mechatronics artificial intelligence equipment and instruments,Production and product agency,Technology Promotion,Sales;biology,medical equipment,Chemical Reagent Technology Development,technical consulting,Technical Services,technology transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)